Brief: GNI Group unit says clearance of IND by FDA for F351 clinical trials in the treatment of liver fibrosis

GNI

02/10/2017 02:28

Oct 2(Reuters) - GNI Group Ltd  2160.T  
     
    * Says its wholly-owned subsidiary GNI USA, Inc had received 
U.S. FDA clearance on Sept. 29 (U.S. local time) for the 
Investigational New Drug application (IND) for F351 for U.S. 
clinical trials in the treatment of liver fibrosis 
 
     
     
    Source text in Japanese:https://goo.gl/wHgB1R 
    Further company coverage: 2160.T  
 
 (Beijing Headline News) 
 ((Beijing.HeadlineNews@thomsonreuters.com; +86 10 62674724; 
Reuters Messaging: huafang.zhang.reuters.com@reuters.net))